The Numbers - Google Finance Research

Insider 1: $7.78 per share - 4,000 shares

Insider 2: $8.14 per share - 7,000 shares

Google: 52 Week Range: ($6.08 - $19.11)

Company Bio

NeoGenomics is a leading cancer diagnostics and pharma services company committed to improving patient care through exceptional genetic and molecular testing services.

They offer a comprehensive suite of oncology tests, including next-generation sequencing and molecular diagnostics, to hospitals, pathologists, and researchers.

With a focus on precision oncology, NeoGenomics aims to provide crucial insights for cancer diagnosis, prognosis, and treatment decisions.

The headquarters of NeoGenomics is located at 9490 NeoGenomics Way, Fort Myers, Florida, 33912, United States.

Recent News

May 1, 2025: NeoGenomics announced that it had paid off in full the remaining $201.25 million principal amount of its 1.25% Convertible Senior Notes that matured on May 1, 2025, using cash on hand.

April 29, 2025: NeoGenomics reported its first-quarter 2025 financial results, showing an 8% increase in consolidated revenue to $168 million compared to the same period in 2024. The company also highlighted a significant 102% increase in adjusted EBITDA to a positive $7 million.

April 7, 2025: NeoGenomics completed its previously announced acquisition of Pathline, LLC, a laboratory based in New Jersey. This acquisition is expected to strengthen NeoGenomics' commercial presence in the Northeast U.S. and broaden access to its oncology testing services.